Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects
Status:
Active, not recruiting
Trial end date:
2023-12-25
Target enrollment:
Participant gender:
Summary
This is an open,single-arm,multicenter phase II clinical study to evaluate the efficacy and
safety of BEBT-908 for injection in the treatment of relapsed or refractory diffuse large
B-cell lymphoma. The study will be divided into two stages: phase Ⅱa and phase Ⅱb. Phase Ⅱa
is an exploratory study, which mainly explores the safe and effective dose and the
relationship between gene and protein markers and drug sensitivity. The main purpose of the
phase Ⅱb study was to evaluate the Objective response rate of BEBT-908 for injection in the
treatment of relapsed or refractory diffuse large B-cell lymphoma, and the secondary study
was to evaluate the disease control rate, progression-free survival, time to response,
duration of response, overall survival and safety tolerance of BEBT-908 for injection in the
treatment of relapsed or refractory diffuse large B-cell lymphoma. The relationship between
the biomarkers of BEBT-908 for injection and the efficacy and safety was evaluated.